诺和诺德美股股价暴涨，公司减肥口服药在美开局稳健

Group 1 - Novo Nordisk's stock surged by 8% on January 16, reaching a peak of $62.02, the highest level since September of the previous year, with a market capitalization of $273.5 billion [1] - The early prescription data for Novo Nordisk's newly launched oral GLP-1 medication for obesity shows promising results, with approximately 3,100 prescriptions in the first week [3] - Comparatively, Eli Lilly's injectable weight loss drug Zepbound garnered about 1,900 prescriptions in its first full week post-launch, indicating a strong start for Novo Nordisk's oral medication [3] Group 2 - Analysts caution that more data is needed to fully assess the early demand for the Wegovy oral medication [4] - The direct sales channel is expected to have significant potential for promoting the oral medication, and analysts are eager to see its complete performance [5] - The weight loss and diabetes medication market is experiencing rapid growth, with Eli Lilly holding a significant market share and preparing to launch its own oral obesity medication [6] Group 3 - The demand landscape may change in the coming months with the anticipated market entry of Eli Lilly's oral drug orforglipron [7] - Although Novo Nordisk currently has a first-mover advantage, its peptide-based medication has dietary restrictions that may affect user acceptance [7] - In contrast, Eli Lilly's drug is a small molecule compound, which does not have the same dietary limitations [8]